Why Research Childhood Cancers with Low Survival Rates?

Researching Childhood Cancers with Low Survival Rates

The Rare Diseases Act of 2002 states that a disease or disorder is considered “rare” if fewer than 200,000 people are affected by it in the United States. Of more than 100 types of cancer[1], only breast and prostate cancers do not qualify as a “rare disease.” Childhood cancers are all “rare diseases” as they make up only 1% of all cancers diagnosed annually. There are 16 major types of cancer that affect children, with a host of subtypes, with some types affecting just dozens or less of children per year in the U.S. This makes any childhood cancer truly ultra-rare, which presents distinct challenges for research and clinical trials to improve survival. Despite this rarity, cancer is the most common cause of disease-related death in children in developed countries.
While there have been dramatic improvements in outcomes for some pediatric cancers[2] such as leukemia (ALL), there are some tumor types that have had no improvement in survival in decades[3], such as metastatic sarcomas and some brain tumors. Chronic and severe late effects from toxic treatments plague the survivors of cancers such as neuroblastoma, and there is a growing and urgent need to improve therapies with less toxic and novel approaches.



The Challenges of Researching Rare Childhood Cancers

● Small Numbers to Accrue on Clinical Trials
Rare childhood cancers are extremely challenging to study in clinical trials because there are so few patients with the same diagnosis. Some tumor types such as ETMR and ATRT are so rare there are no standard protocols developed. Other types such as neuroblastoma or medulloblastoma have seen very slow progress because large randomized trials can take a decade to complete.

For example, it took 25 years for clinical trials to be completed to prove that an antibody given after intense chemotherapy, surgery, and radiation improves outcomes for children with neuroblastoma. Consequently, most protocols still use the same chemotherapy agents introduced 40 years ago.

● Ethics of Research on Children[4] [5]
Children are considered a vulnerable population in medical research because of the limited understanding of the nature of the research and the risk/benefit ratio, which creates unique ethical concerns. In addition, children may be affected by medicines differently than adults due to normal growth and development processes. Children cannot therefore give informed consent to participate in a clinical trial, so policies that govern parental consent are included in the ethical review of clinical trials.[6]

● Need for More Funding and Incentives
With an estimated 7,000 rare diseases[7] described, government funding for the study of each disease is highly competitive. From 1973-1983, less than 10 treatments for rare diseases were approved. Through programs and legislation that incentivize biotechs and pharmaceutical companies to develop treatments for rare diseases, the FDA aims to improve the process of bringing treatments to the market. For example, the Creating Hope Act (2012) established the priority review voucher program, which provides incentives to companies who develop FDA-approved drugs for rare pediatric diseases such as cancer. In addition, the RACE Act[8] (2017) mandated that adult oncology drugs also be tested in children when the molecular targets are relevant to children’s cancers. Both acts radically changed the landscape of drug development for pediatric cancers — stimulating both investment and early regulatory discussions for pediatric testing plans.

Because of the new regulatory landscape, companies are more willing than ever to test their products in children with cancer. However, this requires significant funding to accomplish, especially for biotech startups with novel agents but limited capital to fund pediatric studies. This results in increased demand for philanthropic funding from charities to support critical new trials.

● Lack of Research Cooperation
Today’s research environment also contributes to the difficulty of advancing research for cancers with low survival rates. Limited availability of funds encourages competition rather than collaboration, resulting in frequently uncoordinated efforts. Some agents are advanced even when little or no benefit is demonstrated. Pre-clinical data is often not translated into clinical trials, resulting in missed opportunities to utilize novel agents, approaches, and targets. The lack of a collaborative and coordinated approach across research teams limits the impact on improved survival. One important effort to improve international collaborations is through the multi-stakeholder ACCELERATE platform[9] where Solving Kids’ Cancer serves on working groups with industry, academics, regulatory experts, and leading advocates.

The Benefits of Researching Rare Diseases

Despite the challenges presented by researching rare diseases such as childhood cancers, there are a variety of reasons to invest in this type of research – even for the rarest childhood cancers.

● Scientific Breakthroughs and Discoveries: Investigating the underlying cause of rare diseases can lead to major breakthroughs, such as discovering gene mutations or new disease processes. Scientific breakthroughs can also lead to more publicity and increased awareness about the disease, which often results in more research funding.

● Research is Applicable to Other Disease Spaces: Research or drug development for rare childhood cancers could lead to the development of more effective therapeutics for other diseases that have similar disease processes or underlying causes.

● Every Kid Deserves to Grow Up®: Kids have a longer life ahead of them with more time and opportunity to contribute to society.[10] Despite their young age at diagnosis, children with rare childhood cancers should be entitled to the same quality of treatment as other patients.

Funding Effective Treatments and Breakthroughs for Childhood Cancer

In recent years, nonprofit and medical organizations, researchers, and oncologists have recognized the urgent need to invest in researching childhood cancers with low survival rates. Growing collaboration across the field has created several opportunities to improve the outcomes for children.



For example, several disease-specific registries have been created, aggregating resources among the research community and allowing researchers to gather biological samples from tumors for use in further studies.


Another approach is bringing together the top experts in a particular tumor type to discuss challenges and brainstorm solutions. Solving Kids’ Cancer facilitated satellite and dedicated meetings for medulloblastoma over a three-year period, culminating with a summit in New York in December 2019. This workshop, attended by invited researchers, clinicians, and charity leaders, resulted in three new clinical trial concepts, the first of which is now funded by a collaboration of charities and will test a bold new immunotherapy approach in children with relapsed or refractory medulloblastoma. Solving Kids’ Cancer continues to address unmet needs with plans to bring together key stakeholders from around the world to stimulate bold approaches in other poor-prognosis tumor types.

A group of scientists are working in a laboratory.

By encouraging global collaboration and challenging researchers to think boldly, Solving Kids’ Cancer has helped the field to focus on investigating new treatments and strategies to improve survival rates for rare childhood cancers, such as neuroblastoma and sarcomas, in addition to rare brain tumors in kids. Since 2008, Solving Kids’ Cancer has invested in 41 translational and clinical research projects that include 28 clinical trials testing novel agents and combinations in children. These clinical trials have introduced new antibodies, vaccines, oncolytic viruses, novel delivery, and targeted agents to children in more than 30 countries, and many are showing promise in terms of efficacy and less toxicity.

Every two minutes, a child is diagnosed with cancer. Together, we can solve that. Learn more about our unique approach to finding, funding, and managing clinical trials.

Get the Latest News

Stay up to date on all the latest news, including our new research projects, advances in treatment, upcoming events and more.

Contact Us

By Kristi McKay December 2, 2024
Ways to Give Back During the Holidays
A man and a little girl are sitting in front of a wooden wall.
By duda November 20, 2024
Ahana’s Story of Strength with High-Risk Neuroblastoma Every day, over 1,000 children worldwide are diagnosed with cancer,1 and for many families, that diagnosis means facing an uncertain future. At just 20 months old, Ahana was diagnosed with a rare and aggressive cancer that had already spread through her small body. Her family’s search for life-saving childhood cancer treatments led them from South Africa to Spain and possibly toward a clinical trial in New York. Ahana’s journey shows the importance of supporting organizations like Solving Kids’ Cancer, which works to find, fund, and advocate for advanced treatments that give hope to families fighting against tough-to-treat rare pediatric cancers.
A poster for 2024 year in review for solving kids ' cancer
November 11, 2024
Advancing Childhood Cancer Research: SKC’s 2024 Milestones
A group of children are holding a sign that says
October 1, 2024
Lace Up for Kids: Your Impact on Childhood Cancer Research At Solving Kids’ Cancer, our mission has always been driven by hope — hope for better treatments, hope for breakthroughs, and most importantly, hope for every child fighting cancer. This year’s Lace Up for Kids campaign was nothing short of inspiring. Together, we’ve raised over $264,000 across the entire campaign, funding innovative childhood cancer research and providing more treatment options for children in need.  From coast to coast, nearly 4,000 participants have stepped up to lace up their gold shoelaces and make a difference. Whether it was through schools, sports teams, or community groups, the show of support has been overwhelming throughout the years. Over 7,823 donations have been made to accelerate new treatments, and the hashtag #CareWearShare has been used 13,864 times, spreading the message far and wide!
A girl is standing in front of a car in a parking lot.
September 2, 2024
Gold Laces for Childhood Cancer Awareness Month: Erin’s Story 
A group of children are standing in a circle with their shoes on the floor.
August 8, 2024
Smithtown Goes Gold for Childhood Cancer Awareness Month!
A poster for lace up for kids with a butterfly on it
August 6, 2024
Childhood Cancer Awareness Month: Lace Up for Kids 2024
A man standing on top of a mountain with the words osteosarcoma survivor to surgeon dr. kurt weiss ' story
August 1, 2024
Osteosarcoma Survivor to Surgeon: Dr. Kurt Weiss’ Story
By Kristi McKay July 4, 2024
A Quick Guide to Your Role as a Parent Advocate 
Jacob 's journey : a childhood cancer survivor 's story
May 10, 2024
Jacob’s Journey: A Childhood Cancer Survivor’s Story Every battle has its heroes, and among the bravest are young children like Jacob Mozer, who faced stage 4 high-risk neuroblastoma when he was barely old enough to walk. Diagnosed at only 16 months old, Jacob’s early years were filled with constant medical appointments and intense treatments. Despite these challenges, today, Jacob is a shining example of the remarkable progress in pediatric oncology. He’s not merely surviving; he’s thriving as a pharmacy resident, driven to give back to the medical community that gave him a second chance at life. During National Cancer Survivors Month this June, we honor and celebrate fighters like Jacob who have battled cancer and emerged stronger. This month also serves to amplify the conversation about pediatric cancer survivorship and push for vital research that continues to save lives. Solving Kids’ Cancer (SKC) plays an essential role in this effort, supporting children like Jacob by funding crucial clinical trials that enhance survival rates and improve the quality of life for those fighting fatal childhood cancers.
More Posts